Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naïve Patients With Recurrent Glioblastoma Multiforme

Trial Profile

Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naïve Patients With Recurrent Glioblastoma Multiforme

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carotuximab (Primary)
  • Indications Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 May 2017 According to a TRACON Pharmaceuticals media release, NCI will present detailed survival data and correlative analyses at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2017.
    • 09 Feb 2017 Detailed data and the associated correlative analyses are expected to be presented at an oncology conference later this year, according to a TRACON Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top